Please login to the form below

Not currently logged in
Email:
Password:

FIBRONEER global programme

This page shows the latest FIBRONEER global programme news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim enrols first patient in pulmonary fibrosis phase 3 trial

Boehringer Ingelheim enrols first patient in pulmonary fibrosis phase 3 trial

The trial – FIBRONEER-IPF – is part of the company’s FIBRONEER global programme, comprising two phase 3 studies in patients with IPF and other progressive fibrosing interstitial lung diseases (ILDs). ... Dr Donald Zoz, director and senior clinical

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The challenges of identifying rare diseases
With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...